Healthcare · NYSE/NASDAQ: AMGN
AMGEN INC
Drug Manufacturers—General
Market Cap $189.18B
Verdict: High
Quality Scores
Multi-Bagger
72/100
Compounder Quality
85/100
Management Credibility
82/100
Governance
85/100
Cash Flow Quality
88/100
AI Summary
Amgen Inc. remains a powerhouse in the biotechnology sector, transitioning from a legacy biologics provider to a diversified innovator in oncology, inflammation, and rare diseases. Clinical revenue has Grown from $22.99B in 2016 to $36.75B in 2025, supported by the strategic $27.8B acquisition of Horizon Therapeutics. While net income has shown volatility due to tax reforms (2017) and heavy M&A-related amortization, the underlying operating cash flow remains robustly above $9B annually. The company is successfully navigating the patent cliff of legacy assets like Enbrel by ramping up newer…
Top Opportunities
- Consistent cash flow generation exceeding $8B annually
- Strategic acquisition of Horizon Therapeutics diversifying portfolio
- Aggressive pipeline development in high-growth obesity market (MariTide)
Top Risks
- Significant increase in long-term debt levels since 2023
- Noticeable trend of declining operating margins over the last decade
- Heavy reliance on a few blockbuster drugs (Enbrel) facing competition
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.